Bernstein simply threw contemporary gasoline on Eli Lilly’s (LLY) endless rally, because the agency lifted its worth goal on the inventory to $1,300 from $1,100.
For perspective, that’s an 18% bump in comparison with the outdated goal, whereas representing a 21% to 22% upside in comparison with Lilly’s present inventory worth.
Analyst Courtney Breen feels Wall Avenue nonetheless is not factoring in how huge the corporate’s subsequent wave of GLP-1 catalysts could possibly be.
She feels Lilly’s unimaginable leap into the trillion-dollar membership, as reported by Reuters, wasn’t the highest, and that 2026 could possibly be the turning level the place its illustrious story transitions into real “beat-and-raise” momentum.
Additionally, orforglipron’s approaching launch, White Home coverage is shifting in the direction of broader protection, whereas tirzepatide has advanced into changing into a multi-indication platform.
Therefore, Breen sees a setup providing a ton of upside.
Furthermore, it’s essential to notice that per Tipranks, Breen carries a standout 94% success price, with 32 of her 34 inventory calls turning a revenue.
On prime of that, her suggestions ship a powerful +21.5% common return per score, positioning her among the many prime tier of Wall Avenue analysts.
Bernstein’s Courtney Breen lifted Eli Lilly’s worth goal considerably, citing stronger GLP-1 catalysts forward.Picture by NurPhoto on Getty Photos
Bernstein analyst Breen’s bullishness on Eli Lilly primarily rests on what she dubs as an “extremely wealthy” catalyst path that stretches greater than two years.
Most of it’s right down to how a lot earnings energy Mr. Market hasn’t modeled into the inventory.
On the middle of it’s Lilly’s oral GLP-1 orforglipron, which Breen feels will gasoline the subsequent leg of enlargement for the corporate.
Extra Medicare/Medicaid
That’s partly as a result of a conducive U.S. coverage backdrop that has shifted beneath President Donald Trump’s GLP-1 deal, together with rising world reimbursement channels.
Breen and her staff developed a monetary mannequin slicing Medicare, Medicaid, business, and cash-pay demand on a quarterly schedule working by 2027 and yearly to 2030.
The outcomes confirmed that consensus was nonetheless too conservative on volumes and potential gross sales.
Associated: Cathie Wooden buys the dip in Nvidia-backed inventory
The large breakthrough is predicted to be in 2026.
That’s when orforglipron strikes from promise to revenue engine, with estimated gross sales at an excellent $1.8 billion, which is greater than 3 occasions the Avenue’s view of $550 million.
What’s much more spectacular is that Breen stresses that these lofty numbers are U.S.-only assumptions based mostly on almost 80,000 weekly scripts within the oral weight problems market.
Weight-loss medicine have successfully been the inventory market’s new rocket gasoline of late, and it appears the trajectory isn’t slowing down any time quickly.
The science behind the GLP-1 (i.e, weight reduction medicine) increase is straightforward.
These medicine mainly flip down the amount knob on starvation whereas including pace bumps to your abdomen.
These medicines mimic the intestine hormones launched after we eat, telling our brains we’re full loads faster whereas slowing down gastric emptying and bettering insulin launch within the course of.
The result’s that we get fewer cravings, together with regular weight reduction over time.
Associated: Goldman Sachs, JPMorgan and BofA drop verdicts on Nvidia earnings
Furthermore, estimates counsel that we’re simply getting began on this development journey.
As an example, Morgan Stanley estimates branded weight problems medicine generated a whopping $6 billion in 2023 and almost $15 billion in 2024, in accordance with Morgan Stanley. Additionally, it forecasts the worldwide market to achieve $105 billion by 2030 and presumably $150 billion at peak round 2035.
Equally, JPMorgan sees GLP-1s for diabetes and weight problems collectively contributing $100 billion by 2030.
Injectables Eli Lilly – Mounjaro (tirzepatide) for kind 2 diabetes and Zepbound for weight problems and obstructive sleep apnea (OSA). Novo Nordisk – Ozempic (semaglutide) for diabetes and Wegovy for weight problems; helped push Novo’s obesity-care gross sales alone to DKK 65.1 billion ($9.5 billion) in 2024.
Drugs (in market or late-stage pipeline) Novo Nordisk – oral semaglutide (Rybelsus/high-dose 50 mg): Within the OASIS-1 trial, 50 mg once-daily oral semaglutide resulted in almost a 15% common weight reduction (17% in adherent sufferers). Eli Lilly – orforglipron: A once-daily small-molecule GLP-1 capsule; Part 3 knowledge present round 9 to 10% common weight reduction over 72 weeks versus 2 to three% with placebo.
Lilly constructed its approach as much as the trillion-dollar membership, reaching the feat on November 21, spearheaded by its strong GLP-1 engine.
The corporate’s weight-loss breakthrough has successfully grow to be a full-blown metabolic-health franchise, led by tirzepatide’s dominance, together with a string of medical wins.
The numbers clarify why buyers purchased into its story, with hovering gross sales, tech-style margins, and a pipeline that continues rising its addressable market.
Now with an oral GLP-1 on deck, the flywheel that simply pushed Lilly to $1 trillion remains to be accelerating.
File-smashing GLP-1 gross sales: In Q3 2025, BioPharma Dive reported tirzepatide merchandise posted $10 billion+, together with $6.5 billion from Mounjaro (+109% yr over yr) and $3.6 billion from Zepbound (+185% YoY), lifting complete gross sales 54% yr over yr to $17.6 billion.
A pipeline that stored enlarging the market:In response to JAMA Community, Zepbound’s OSA approval (sleep apnea) shaped a model new reimbursable class, whereas tapping a inhabitants estimated close to 1 billion folks globally.
Tech-style profitability: EPS hit $7.02, margins moved into the mid-80s, whereas its valuation jumped almost 200% prior to now three years.
Subsequent-gen enlargement: Orforglipron’s sturdy Part 3 knowledge positions Lilly to dominate each the injectable and oral GLP-1 markets heading into 2030.
Associated: Tesla will get eye-popping message from newest survey
This story was initially revealed by TheStreet on Nov 25, 2025, the place it first appeared within the Investing part. Add TheStreet as a Most popular Supply by clicking right here.
